Epidemiology of Cervical Cancer and Contributing Factors in HIV-Positive Women Attending Public Hospitals in Amhara Region, Ethiopia: A Cross-Sectional Analysis for 2025 - Takeaways - MDSpire

Epidemiology of Cervical Cancer and Contributing Factors in HIV-Positive Women Attending Public Hospitals in Amhara Region, Ethiopia: A Cross-Sectional Analysis for 2025

  • By

  • Muluken Belachew Mengistie

  • Wubete Lule Ayalew

  • Simane Kefale Mengistie

  • Ayenew Sisay Gebeyehu

  • Sefefe Birhanu Tizie

  • Ashagrie Anteneh Mekonen

  • Mezigebu Lule Ayalew

  • February 28, 2026

  • 0 min

Share

  • 1

    Cervical cancer is the second most common malignancy among women globally, with a significant burden in low-income countries due to inadequate screening.

  • 2

    Women living with HIV are at a higher risk for cervical cancer due to compromised immune function and increased susceptibility to HPV.

  • 3

    In Ethiopia, cervical cancer is a leading cause of morbidity and mortality among women, with many presenting at advanced stages.

  • 4

    Effective screening and HPV vaccination are critical for reducing cervical cancer incidence and mortality, especially among women living with HIV.

  • 5

    The study aims to assess the prevalence of cervical cancer and associated factors among women living with HIV in the Amhara Region of Ethiopia.

Original Source(s)

Epidemiology of Cervical Cancer and Contributing Factors in HIV-Positive Women Attending Public Hospitals in Amhara Region, Ethiopia: A Cross-Sectional Analysis for 2025

  • by Muluken Belachew Mengistie, Wubete Lule Ayalew, Simane Kefale Mengistie, Ayenew Sisay Gebeyehu, Sefefe Birhanu Tizie, Ashagrie Anteneh Mekonen, Mezigebu Lule Ayalew

  • February 28, 2026

Related Content

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer